To support the launch of a new generation of products, UCB, the biopharmaceutical company specialized in neurology and immunology, is investing 300 million euros in the construction of an ultra-modern biological production plant at its site in Braine-l’Alleud. The plant should be operational in 2024 and should create 150 direct jobs.
This new infrastructure is intended to support the global company in its strategic transformation. UCB was mainly specialized in the production of ‘small molecule’ chemical drugs, often in tablet form. The group is now increasingly focusing on biologics, large therapeutic proteins, such as monoclonal antibodies. The company’s ambition is to transform the lives of people living with serious diseases by putting patients at the centre of the business.
UCB has a promising pipeline of new molecules to ensure continued and sustainable growth. The company aims to minimize its environmental footprint and to be carbon neutral by 2030. The new plant is fully in line with this commitment to eco-responsibility and complies with the strictest environmental standards.
The site at Braine-l’Alleud is one of the group’s strategic centres, combining research, development, and production. This investment further anchors the Walloon site on the global biotechnology map.